





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































	 Alexishafen	Cohort	 FIS	Cohort	 P	value	
Number	of	pairs	 157	 143	 	
Maternal	Characteristics	 	 	 	
			Maternal	age	in	years,	mean	(range)		 25.4	(16-49)	 25	(16-42)	 0.543	
			Gravidity,	mean	(range)	 2.77	(1-10)	 1.8	(1-8)	 <0.001	
			Primigravid,	n	(%)	 54	(34.4%)	 70	(48.9%)	 0.012	
			Maternal	hemoglobin	at	delivery	in	g/dL,	mean	(range)	 9.3	(4.2	–	14.2)	 9.67	(5.5	–	13.9)	 0.097	
			Anemic,	defined	as	≤9	g/dL,n	(%)	 63	(40%)	 25	(17%)	 <0.001	




			Birth	weight	in	grams,	mean	(range)	 3007	(2050	–	5700)	 3057	(2100-4400)	 0.324	
			Low	birth	weight,	defined	as	<2500g,	n	(%)	 11	(7%)	 10	(6.9%)	 0.996	
			Female,	n	(%)	 70	(46.4%)	 69	(48.3%)	 0.7451	
Placental	Malaria	by	Histology	 	 	 	
Number	of	pairs	with	histology	available	 153	 137	 	
			Placental	malaria	positive	(stage	1-4),	n	(%)	 93	(60.2%)	 12	(8.8%)	 <0.001	
			Placental	malaria	negative	(stage	5)	n	(%)	 60	(39.2%)	 125	(91.2%)	 <0.001	
			Stage	2	–	Acute:	parasites,	pigment	in	monocytes	+/-	fibrin	 20	(13%)	 0	 <0.001	
			Stage	3	–	Chronic:	parasites,	pigment	in	fibrin	 3	(2.0%)	 1	(0.7%)	 0.361	
			Stage	4	–	past	infection	 12	(7.8%)	 4	(2.9%)	 0.062	
Peripheral	Blood	PCR		 	




			Negative	by	PCR	at	delivery	(maternal	peripheral	blood)	 90	(57.3%)	 136	(97.1%)	 <0.001	
			Positive	by	PCR	at	delivery	(maternal	peripheral	blood)	 67	(42.7%)	 4	(2.9%)	 <0.001	
Maternal	IgG	 	 	 	
		Mean	(range)	 2004	(727.8	–	7514.3)	 1110	(501	–	2726.2)	 <0.001	












Alexishafen	Cohort	 	 	 	 	 	
All	 254.3	(11-7150)	 301.7	(21.4	–	3257)	 1.19	(0.22-4.54)	 0.17	 0.34	
Placental	Malaria	+	 220.4	(23-7150)	 256.0	(33	–	3257)	 1.16	(0.22	–	4.24)	 0.17	 0.37	
Placental	Malaria	-	 303.0	(11-3329)	 371.7	(21.4	–	3191)	 1.23	(0.32	–	4.54)	 0.17	 0.32	
	 P=0.02	 P=0.007	 P=0.8	 OR	1.04	[0.40	–	2.77]	P=0.9	 OR	1.24	[0.59	–	
2.64]	P=0.53	
Hypergammaglobulinemia	+	 305.1	(11-7150)	 332.4	(21.4	–	3257)	 1.09	(0.22	–	4.55)	 0.22	 0.42	
Hypergammaglobulinemia	-	 205.1	(23-1973)	 269.1	(33-2870)	 1.31	(0.40	–	3.99)	 0.11	 0.25	
	 P=0.004	 P=0.159	 P=0.014	 OR	2.3	[0.88-6.5;	P=0.06]	 OR	2.2	[1.05	–	4.66,	P=0.02]	
FIS	Cohort	 	 	 	 	 	
All	 239.1	(19.5	–	2259)	 291.0	(23.1-2592)	 1.22	(0.29	–	3.88)	 0.18	 0.32	
Placental	Malaria	+	 229.9	(58.7	–	587.9)	 300.9	(78.3	–	869.3)	 1.30	(0.71	–	2.55)	 0.08	 0.25	
Placental	Malaria	-	 246.0	(19.5	–	2259)	 295.2	(23.1	-2592.8)	 1.2	(0.29	–	3.88)	 0.2	 0.34	
	 P=0.81	 P=0.78	 P=0.52	 OR	0.36	[0.008	–	2.74]	P=0.46	 OR	0.64	[0.11	-2.73]	P=0.75	
Hypergammaglobulinemia	+	 368.5	(87.1	–	2032)	 353.2	(192.4	-	836)	 0.96	(0.41	–	2.58)	 0.50	 0.67	
Hypergammaglobulinemia	-	 229.8	(19.5	–	2259)	 285.9	(23.1	–	2598)	 1.24	(0.29	–	3.88)	 0.15	 0.29	










CMTR	<0.8	 	 	 	 	 	
Placental	Malaria	 1.11	(0.43-2.87)	 0.822	 	 0.237	(0.024-2.27)	 0.212	
Maternal	IgG	 2.93	(1.10-7.74)	 0.03	 	 5.95	(1.32-26.77)	 0.02	
CMTR	<1.0	 	 	 	 	 	
Placental	Malaria		 1.36	(0.647-2.87)	 0.415	 	 0.44	(0.099-1.94)	 0.280	
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Severity	 Negative	 Positive	 Total	 Odds	Ratio	 CI	 P-value	
PAF	[OR	–	
(1/OR)]	
RSV	 	 	 	 	 	 	 	
No	pneumonia	 13	 1	 14	 0.70	 (0.015	-	5.08)	 NS	 	
Non-severe	 229	 25	 254	 ref	 -	 -	 	
Severe	 38	 11	 49	 2.65	 (1.08	-	6.13)	 0.012	 56%	
Very	Severe	 41	 2	 43	 0.47	 (0.49	-	1.91)	 NS	 	
	 	 	 	 	 	 	 	
Rhinovirus		 	 	 	 	 	 	 	
No	Pneumonia	 6	 8	 14	 1.82	 0.53	–	6.54	 NS	 	
Non-Severe	 147	 107	 254	 ref	 -	 -	 -	
Severe	 33	 16	 49	 0.66	 0.32	–	1.31	 NS	 -	
Very	Severe	 23	 20	 43	 1.18	 0.58	–	2.4	 NS	 	
	 	 	 	 	 	 	 	
Bocavirus	 	 	 	 	 	 	 	
No	Pneumonia	 10	 4	 14	 1.07	 (0.23	–	3.88)	 NS	 	
Non-Severe	 185	 69	 254	 ref	 -	 -	 	
Severe	 33	 16	 49	 1.29	 (0.63	–	2.61)	 NS	 	
Very	Severe	 31	 12	 43	 1.04	 (0.46	–	2.22)	 NS	 	
	 	 	 	 	 	 	 	
Adenovirus	 	 	 	 	 	 	 	
No	Pneumonia	 11	 3	 14	 0.92	 (0.16	–	3.65)	 NS	 	
Non-Severe	 196	 58	 254	 ref	 -	 -	 	
Severe	 37	 12	 49	 1.10	 (0.49	–	2.23)	 NS	 	
Very	Severe	 32	 11	 43	 1.16	 (0.50	–	2.55)	 NS	 	
	 	 	 	 	 	 	 	

















	 	 	 	 	 	
Adenovirus	 3	(21)	 58	(23)	 12	(25)	 11	(26)	 	
Bocavirus	 4	(29)	 69	(27)	 16	(33)	 12	(28)	 	
Coronavirus	229E	 -	 -	 -	 -	 	
Coronavirus	OC43	 -	 11	(4)	 1	(2)	 2	(5)	 	
Coronavirus	NL63	 -	 7	(3)	 1	(2)	 1	(2)	 	
Coronavirus	HKU1	 -	 4	(2)	 -	 -	 	
Entervorus	 -	 8	(3)	 -	 -	 	
Human	metapneumovirus	A/B	 -	 4	(2)	 1	(2)	 0	 	
Influenza	A	(non	H1N1)	 -	 5	(2)	 2	(4)	 0	 	
Influenza	A	(H1N1)	 -	 4	(2)	 1	(2)	 0	 	
Influenza	B	 2	(14)	 16	(6)	 1	(2)	 1	(2)	 	
Parainfluenza	1	 -	 2	(1)	 -	 -	 	
Parainfluenza	2	 -	 1	(0.4)	 1	(2)	 0	 	
Parainfluenza	3	 -	 11	(4)	 1	(2)	 4	(9)	 	
Parainfluenza	4	 -	 10	(4)	 -	 1	(2)	 	
Parechovirus	(PV)	 2	(14)	 1	(0.4)	 -	 -	 0.012	
Rhinovirus	 8	(57)	 107	(42)	 16	(33)	 20	(47)	 	
RSV	A/B	 1	(7)	 25	(10)	 11	(23)	 2	(5)	 0.044	
	 	 	 	 	 	














Non-severe	pneumonia	 362	(56%)	 285	(44%)	 647	
Severe	pneumonia	 63	(62%)	 39	(38%)	 102	
Very	severe	pneumonia	 78	(63%)	 46	(37%)	 124	
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Figure	4.3:	Viral	detection	by	age	
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	 All	RSV+	in	2013	 RSV+	Subset	 P-value	
N	 846	 524	 	
Male;	n(%)	 489	(58)	 308	(59)	 	
Gestational	age;	mean	(range)	 38	(25-43)	 38	(25–42)	 	
Birth	weight	in	g;	mean	(range)	 3196	(715-8730)	 3172	(715–4650)	 	
IUGR;	n(%)	 31	(3.7)	 22	(4)	 	
	Admitted	to	NICU	when	born;	n(%) 163	(19)	 101	(19)	 	
Vaccines	up	to	date;	n(%)	 398	(47)	 257	(49)	 	
Previous	episodes	of	wheeze;	n(%)	 145	(17)	 95	(18)	 	
Congenital	heart	disease;	n(%)	 19	(2.3)	 11	(2)	 	
Down	Syndrome;	n(%)	 5	(0.6)	 3	(0.6)	 	
Neurologic	condition;	n(%)	 9	(1)	 6	(1.2)	 	
Asthma	-	mother;	n(%)	 35	(4)	 24	(4.6)	 	
Asthma	-	father;	n(%)	 46	(5)	 33	(6.3)	 	
Previous	admission	to	the	hospital;	n(%)	 192	(23)	 121	(23)	 	
Mother	smokes	cigarettes;	n(%)	 174	(21)	 107	(20)	 	
Father	smokes	cigarettes;	n(%)	 365	(43)	 231	(44)	 	
Mother	completed	secondary	school;	n(%)	 169	(20)	 110	(21)	 	
Father	completed	secondary	school;	n(%)	 161	(19)	 103	(20)	 	
Number	of	siblings;	mean(range)	 1.8	(0-12)	 1.7	(0-10)	 	
Household	size;	mean(range)	 5.4	(1-21)	 5.4	(1-21)	 	
Dirt	floor	at	home;	n(%)	 18	(2)	 12	(2.3)	 	
Running	water	in	the	home;	n(%)	 627	(74)	 404	(77)	 	
Sewage	system	at	home;	n(%)	 301	(36)	 195	(37)	 	
Heating	at	home:	wood/kerosene;	n(%)	 12	(1.4)	 7	(1.3)	 	
At	Hospitalization	 	 	 	
Age	in	months	(mean,	range)	 5.4	(0-24)	 6.2	(0-24)	 0.02	
Fever	when	admitted;	n(%)	 266	(31)	 166	(32)	 	
Tachypnea	n(%)	 402	(48)	 313	(60)	 0.005	
Tachycardia;	n(%)	 349	(59)	 284	(54)	 	
Indrawing-	any;	n(%)	 725	(86)	 482	(92)	 <0.001	
Lower	chest	wall	indrawing;	n(%)	 515	(61)	 361	(69)	 0.001	
Wheezing;	n(%)	 589	(70)	 299	(76)	 0.001	
Nasal	Flaring;	n(%)	 54	(6.4)	 32	(6)	 	
Cough;	n(%)	 534	(63)	 359	(69)	 0.0027	
Apnea;	n(%)	 11	(1.3)	 7	(1.3)	 	
Arrived	ventilated;	n(%)	 112	(13)	 n/a	 	
Required	O2	during	admission;	n(%)	 813	(96)	 513	(98)	 0.02	
CannulaŦ;	n(%)	 659	(78)	 439	(84)	 <0.001	














N	 450	 74	 	
Male;	n(%)	 267	(59)	 41	(55)	 	
Gestational	age;	mean	(range)	 38	(25-42)	 38	(31-42)	 	
Birth	weight	in	g;	mean	(range)	 3180	(715-4650)	 3121	(800-4550)	 	
IUGR;	n(%)	 19	(4)	 3	(4)	 	
	Admitted	to	NICU	when	born;	n(%) 89	(20)	 12	(16)	 	
Vaccines	up	to	date;	n(%)	 221	(49)	 36	(49)	 	
Previous	episodes	of	wheeze;	n(%)	 83	(18)	 12	(16)	 	
Congenital	heart	disease;	n(%)	 9	(2)	 2	(2.7)	 	
Down	Syndrome;	n(%)	 1	(0.2)	 2	(2.7)	 0.009	
Neurologic	condition;	n(%)	 5	(1.0)	 1	(1.4)	 	
Asthma	-	mother;	n(%)	 23	(5)	 1	(1.4)	 	
Asthma	-	father;	n(%)	 32	(7)	 1	(1.4)	 0.05	
Previous	admission	to	the	hospital;	n(%)	 104	(23)	 17	(23)	 	
Mother	smokes	cigarettes;	n(%)	 90	(20)	 17	(23)	 	
Father	smokes	cigarettes;	n(%)	 198	(44)	 33	(45)	 	
Mother	completed	secondary	school;	n(%)	 97	(22)	 13	(17)	 	
Father	completed	secondary	school;	n(%)	 82	(18)	 21	(28)	 0.04	
Number	of	siblings;	mean(range)	 1.6	(0-10)	 2.3	(0-9)	 0.004	
Household	size;	mean(range)	 5.3	(1-21)	 5.7	(2-15)	 	
Dirt	floor	at	home;	n(%)	 11	(2)	 1	(1.4)	 	
Running	water	in	the	home;	n(%)	 354	(79)	 50	(68)	 0.024	
Sewage	system	at	home;	n(%)	 181	(40)	 14	(19)	 0.0004	
Heating	at	home:	wood/kerosene;	n(%)	 6	(1)	 1	(1.4)	 	
	 	 	 	
At	Hospitalization	 	 	 	
Age	in	months	(mean,	range)	 6.2	(0-24)	 6.2	(1-24)	 	
Fever	when	admitted;	n(%)	 154	(34)	 12	(16)	 0.002	
Tachypnea	n(%)	 255	(57)	 58	(78)	 0.0004	
Tachycardia;	n(%)	 229	(51)	 55	(74)	 0.004	
Indrawing-	any;	n(%)	 410	(91)	 72	(97)	 [0.07]	
Lower	chest	wall	indrawing;	n(%)	 305	(68)	 56	(76)	 	
Wheezing;	n(%)	 337	(75)	 62	(84)	 	
Nasal	Flaring;	n(%)	 28	(6)	 4	(5)	 	
Cough;	n(%)	 307	(68)	 52	(70)	 	
Apnea;	n(%)	 6	(1)	 1	(1.4)	 	
Arrived	ventilated;	n(%)	 n/a	 n/a	 	
Required	O2	during	admission;	n(%)	 439	(98)	 74	(100)	 	
CannulaŦ;	n(%)	 439	(98)	 n/a	 	




Variable	 Unadjusted	OR	 95%	CI	 P-value	 Adjusted	OR	 95%	CI	 P-value	
SpO2	≤90	at	admission	 2.29	 1.30	–	4.08	 0.004	 2.30	 1.26	–	4.24	 0.007	
Fast	Breathing	 2.77	 1.54	–	4.97	 0.001	 2.22	 1.19	–	4.16	 0.012	
Tachycardia	 2.29	 1.30	–	4.05	 0.003	 2.35	 1.22	–	4.50	 0.010	
Fever	(≥38°C)	 0.37	 0.19	–	0.71	 0.003	 0.31	 0.15	–	0.61	 0.001	
Subcostal	indrawing	 1.11	 0.61	–	2.03	 0.727	 n/a	 	 	
Wheeze	 1.73	 0.90	–	3.33	 0.099	 n/a	 	 	
Nasal	flaring	 0.86	 0.29	–	2.53	 0.786	 n/a	 	 	
Cough	 1.10	 0.64	–	1.88	 0.725	 n/a	 	 	
Age	in	months	 0.99	 0.95	–	1.05	 0.952	 0.96	 0.90	–	1.02	 0.196	
Sex	 0.85	 0.52	–	1.40	 0.525	 0.93	 0.55	–	1.58	 0.78	
Underweight	 1.01	 0.48	–	2.16	 0.968	 1.02	 0.46	–	2.26	 0.962	
















































































































































































































































































































































!PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET APPROVED! ! !
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Monitoring and Evaluation Team, Policy and Performance Group 
August 2012 – January 2013 
 
• Impact modeling for Hepatitis B-containing vaccines across all Gavi countries from 
2000 to 2020 as part of the 2012-2013 Decade of Vaccines collaboration.  
 
	 	 	 	 	 								
PATH, Ferney-Voltaire, France 
Project OPTIMIZE 
December 2011 – February 2012  
 
• Assisted project OPTIMIZE staff in preparation of a report for the Bill and 
Melinda Gates Foundation assessing country cold chain capacities 
• Focused on identifying potential bottlenecks for all countries planning to introduce 
pneumococcal and/or rotavirus vaccines with support from Gavi in 2011-2015. 
 
 
Gavi (The Vaccine Alliance), Geneva, Switzerland 
Monitoring and Evaluation Team, Policy and Performance Group 
August 2011 – January 2012 
 
• Assisted secretariat with design and drafting of a new tool for immunization data 
quality assessment.  
• Conducted impact modeling for Hepatitis B-containing vaccines across all Gavi 






Health and Economic Benefits Working Group, 2012-2013 Decade of Vaccines 
Collaboration that contributed to the development of the Global Vaccine Action Plan 
 
Members: Jessica Atwell (Johns Hopkins University), Dagna Constenla (Johns Hopkins 
University), S. Deblina Datta (Gavi), Ingrid Friberg (Johns Hopkins University), Marta 
Gacic-Dobo (WHO), Sue Goldie (Harvard School of Public Health), Peter Hansen (Gavi), 
Lisa Lee (Gavi), Orin Levine (Johns Hopkins University), Meredith O’Shea (Harvard School 
of Public Health), Sachiko Ozawa (Johns Hopkins University), Susan Reef (CDC), Meghan 
Stack (Johns Hopkins University), Peter Strebel (WHO), Chutima Suraratdecha (PATH), 
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Steven Sweet (Harvard School of Public Health), Yvonne Tam (Johns Hopkins University), 
Emilia Vynnycky (Health Protection Agency), Damian Walker (Bill & Melinda Gates 





Peer Review Activities 
 
Pediatrics (4)  
2013 - Current  
 
 
HONORS AND AWARDS 
 
 
2015   The Clements-Mann Fellowship in Vaccine Sciences 
   Johns Hopkins Bloomberg School of Public Health 
   Baltimore, MD 
 
2015   The Ludwig Family Award 
Johns Hopkins Bloomberg School of Public Health 
   Baltimore, MD 
 
2015   Distinguished Student Award 
Johns Hopkins Bloomberg School of Public Health 
    Baltimore, MD 
 
2015   The David J. Sencer Scholarship  
   EIS Alumni Association 
   Atlanta, GA 
  
2014    First place poster 
    9th International Respiratory Syncytial Virus Symposium 
    Stellenbosch, South Africa 
 
2014   Young Investigator Award, second tier mention 
Annual meeting of the American Society of Tropical Medicine & 
Hygiene (ASTMH) 
New Orleans, LA 
      
2014   Second place poster 
    Vaccine Day Student Poster Competition 
Johns Hopkins Bloomberg School of Public Health 
    Baltimore, MD 
 
2013   First place poster 
    Delta Omega Poster Session, GDEC sub-competition 
Johns Hopkins Bloomberg School of Public Health 




2012   First place poster 
Vaccine Day Student Poster Competition 
Johns Hopkins Bloomberg School of Public Health 
    Baltimore, MD 
 
2013   The Clements-Mann Fellowship in Vaccine Sciences 
    Johns Hopkins Bloomberg School of Public Health 
    Baltimore, MD 
 
2011   Travel Fellowship (to support internship at Gavi) 
Center for Immunization Research 
    Johns Hopkins Bloomberg School of Public Health 
    Baltimore, MD 
 
 
 2011   MPH Capstone Award for Outstanding Achievement 
Johns Hopkins Bloomberg School of Public Health 
    Baltimore, MD 
 
2007   Superior Performance Award 
    California Department of Public Health 
    Richmond, CA 
 
2005   UCSB Student Volunteer Appreciation Award 
    University of California, Santa Barbara 
    Santa Barbara, CA 
 
2005   Dean’s List 
    University of California, Santa Barbara 
Santa Barbara, CA 
 
2004   Most Appreciated Volunteer 
    2004 Santa Barbara AIDS Walk 
    Santa Barbara, CA 
 
2000   UC Regents Academic Scholarship 
    University of California, Santa Barbara 
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Solicited Commentaries  
 
8. Atwell, J.E., Salmon, D.A.  Pertussis resurgence and vaccine uptake: Implications for 




















 Vaccine Development and Application (223.622.01) 
Department of International Health 
 Johns Hopkins Bloomberg School of Public Health 
 
  Lecture Title: Bacterial Vaccines and Toxoids: Diphtheria, tetanus and pertussis  
October 2015, October 2014 
 
  Lecture Title: Pertussis 






Johns Hopkins Bloomberg School of Public Health 
Department of International Health 
 
 
2012, 2013, 2015 Global Disease Control Programs and Policies (223.680.01) 
Primary Instructors: Drs. Christian Cole and Alain Labrique 
Grading TA 
 
2011, 2012, 2013, 2014  Vaccine Development and Application, onsite (223.622.01) 
Primary Instructors: Drs. Ruth Karron and Laura Hammitt (2013, 
2014); Dr. Neal Halsey (2011, 2012)  
 
2011, 2012   Vaccine Development and Application, online (223.622.81) 
Primary Instructor: Dr. Neal Halsey 
 
2011, 2012   Special Topics in Vaccine Science (223.867.01) 
   Primary Instructor: Dr. Anna Durbin 
 
2011    Introduction to Global Health (undergraduate) 
   Primary Instructor: Dr. Jim Tielsch 
     
 
Johns Hopkins Bloomberg School of Public Health 
Department of Epidemiology 
 
     
2013, 2014   Fundamentals of Epidemiology, online (550.694.81) 
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Primary Instructors: Drs. Marie Diener-West and Sukon 
Kanchanaraksa 
 
2012, 2013   Principles of Epidemiology, summer term (340.601.01) 
Primary Instructors: Drs. Rosa Crum and Greg Kirk 
 
2011, 2012, 2013  Principles of Epidemiology, first term (340.601.01) 






2013, 2014, 2015  Principles of Epidemiology Tutor 
    Department of Epidemiology 





2013 Advisor to: Aaron Chang, Amanda Valledor, Dominic Thomas, 
Allison Moyer, Jin Ryang Chung, Erik Tan, Paola Donis, Rajiv 
Deshpande (Undergraduate Students in Biomedical Engineering) 
  
Senior design project: Facilitating controlled temperature chain 
strategies for last mile vaccine transport 
 
Johns Hopkins University 
    Baltimore, MD 
 
    
 
RESEARCH GRANT PARTICIPATION 
 
Biologic barriers to transplacental antibody transfer, respiratory syncytial virus (RSV) burden, 
and the relationship between cord blood RSV neutralizing antibody and RSV lower 
respiratory infection  
 
2014 - 2015 
PATH Vaccine Solutions 




1. To confirm and extend our group’s previous findings concerning transplacental transfer 
of RSV neutralizing antibody in women and infants living in coastal Papua New Guinea 
(PNG) 
2. To assess the contributions of RSV and other respiratory viruses to acute lower 
respiratory illness (ALRI) in a birth cohort of infants in coastal PNG 
3. To explore the relationship between cord RSV neutralizing antibody titer and RSV 
ALRI in the first year of life in a birth cohort of infants in coastal PNG  
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Principal responsibilities as a Graduate Student Investigator: Travel to the field site in Papua 
New Guinea to support the parent study this project was nested within, and to assist with 
specimen handling, shipping, data entry, data cleaning and interim analysis. To receive, 




Assessment of the effect of placental malaria on transplacental transport of respiratory 
syncytial virus (RSV) antibodies in Papua New Guinea 
 
2012 - 2014 
PATH Vaccine Solutions 




1. To determine the efficiency of transplacental transfer of RSV neutralizing antibody in 
the context of placental malaria by measuring RSV neutralizing antibody titers in paired 
maternal and cord sera from two cohorts of women in Papua New Guinea, where both 
P. falciparum and P. vivax malaria are prevalent 
2. To evaluate the effect of hypergammaglobulinemia on transplacental transfer of RSV 
antibodies in these same cohorts in PNG 
3. To evaluate high-throughput neutralizing antibody assays for RSV to aid in the 
standardization of RSV antibody measurement in the context of clinical trials for RSV 
vaccines 
 
Principal responsibilities as a Graduate Student Investigator: Receive, organize and catalogue 







Scientific Meeting Presentations 
 
Impact of maternal malaria and hypergammaglobulinemia on transplacental transfer of RSV 
neutralizing antibodies in coastal Papua New Guinea  
 
Oral presentation for poster competition finalists (first place) 
9th International Respiratory Syncytial Virus Symposium 
November 2014 
 Stellenbosch, South Africa  
 
 
Impairment of transplacental transfer of antibody  
 
Symposium 79: Maternal Immunization to Prevent Early Infant Respiratory 
Infections and Sepsis: On the Near Horizon 
Annual meeting of the American Society of Tropical Medicine & Hygiene  
November 2014 




Impact of maternal malaria and hypergammaglobulinemia on transplacental transfer of RSV 
neutralizing antibodies in coastal Papua New Guinea. Atwell, J.E., Thumar, B., Robinson, 
L.J., Tobby, R., Yambo, P., Ome-Kaius, M., Stanisic, D.I., Siba, P.M., Unger, H.W., 
Rogerson, S.J., King, C.L., Karron, R.A. 
 
 
Malaria in Pregnancy Symposium 
Johns Hopkins Malaria Research Institute 








9th International Respiratory Syncytial Virus Symposium 





Annual meeting of the American Society of Tropical Medicine & Hygiene  
 New Orleans, LA 
November 2014 
Poster #1119 
Young Investigator Award, second tier mention 
  







Nonmedical Vaccine Exemptions and Pertussis in California, 2010. Atwell, J.E., Van 
Otterloo, J., Zipprich, J., Winter, K., Harriman, K., Salmon, D.A., Halsey, N.A., Omer, S.B 
 
 
Johns Hopkins School of Public Health Delta Omega Poster Competition  
February 2013 
Baltimore, MD 
First place – GDEC sub-competition 
 







GAVI’s Immunization data quality assessment project: Developing a toolbox to evaluate 
country immunization coverage estimates. Atwell, J.E. 
 





Pertussis in California 2005-2010: Epidemiology and geographic distribution of cases and 
personal belief exemptions. Atwell, J.E., Halsey, N.A.   
 
Johns Hopkins School of Public Health Vaccine Day 
October 2011 
Baltimore, MD 
 
	
